01—Abstract
Summary
Summary of the 10-K filed February 21, 2025. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc.'s 2024 10-K filing reveals a significant transition as the company moves from a pandemic-driven revenue model to a more diversified, seasonal commercial approach.
While net product sales declined to $3.1 billiona in 2024 from $6.7 billion in 2023, primarily due to decreased COVID vaccine demand, the company secured regulatory approval for its second commercial product, mRESVIA (RSV vaccine) for older adults. This diversification is crucial as the COVID vaccine market normalizes and faces increased competition. The company continues to invest heavily in research and development, with 44 programs in its pipeline, 11 of which are in late-stage development.
Key advancements include positive Phase 3 data for its next-generation COVID vaccine (mRNA-1283), RSV vaccine for high-risk adults (mRNA-1345), and a flu+COVID combination vaccine (mRNA-1083). The individualized neoantigen therapy (INT) for melanoma, developed with Merck, is also progressing with Phase 3 enrollment completed. Financially, Moderna reported a net loss of $3.6 billionb for 2024, a notable improvement from the $4.7 billion loss in 2023, but still reflecting substantial R&D investments and the strategic resizing of its COVID vaccine operations.
The company maintains a strong liquidity position with $9.5 billionc in cash, cash equivalents, and investments as of December 31, 2024, providing runway for ongoing development and strategic initiatives. Key risks highlighted include evolving market dynamics for respiratory vaccines, intense competition, and the inherent uncertainties in drug development and regulatory approvals.
02—Key points
Key Highlights
- Net product sales decreased to $3.1 billion in 2024, down from $6.7 billion in 2023, primarily due to lower COVID vaccine demand and market normalization.
- Received FDA approval for its second commercial product, mRESVIA (RSV vaccine) for adults aged 60 and older.
- Advanced its pipeline with 11 programs in late-stage development and positive Phase 3 data for several key candidates, including next-generation COVID, RSV, and flu+COVID combination vaccines.
- Reported a net loss of $3.6 billion in 2024, an improvement from $4.7 billion in 2023, reflecting continued R&D investment and cost optimization efforts.
- Maintained a strong liquidity position with $9.5 billion in cash, cash equivalents, and investments as of December 31, 2024.
- Faces significant competition in the vaccine market, particularly for COVID and RSV vaccines, and highlights the uncertainty in forecasting future demand and vaccination rates.
- The individualized neoantigen therapy (INT) for melanoma, developed with Merck, is progressing with Phase 3 enrollment complete and showing sustained benefit.
03—One dollar
Follow one dollar
For each $1.00 of revenue in FY2024, Moderna, Inc. lost $1.10.
- Revenue$3.24B100.0%
- Cost of revenue−$1.46B45.2%
- Gross profit$1.77B54.8%
- Operating costs−$5.72B176.7%
- Operating income−$3.94B121.9%
- Interest, other & tax$384.0M11.9%
- Net income−$3.56B110.0%
04—Financials
Financial Highlights
Figures from 10-KFY2024filed February 21, 2025Financial Statements
FY2024 against FY2023
| Line item | FY2024FY2023 | Change |
|---|---|---|
| Revenue | $3.24B$6.85B | −52.7% |
| Cost of Revenue | $1.46B$4.69B | −68.8% |
| Gross Profit | $1.77B$2.15B | −17.8% |
| R&D Expenses | $4.54B$4.84B | −6.2% |
| Operating Expenses | $7.18B$11.09B | −35.2% |
| Operating Income | -$3.94B-$4.24B | +6.9% |
| Net Income | -$3.56B-$4.71B | +24.5% |
| EPS (Basic) | $-9.28$-12.33 | +24.7% |
| EPS (Diluted) | $-9.28$-12.33 | +24.7% |
| Shares Outstanding (Basic) | 384.00M382.00M | +0.5% |
| Shares Outstanding (Diluted) | 384.00M382.00M | +0.5% |
05—Questions
Frequently Asked Questions
What is Moderna's financial performance in 2024, and what are the key drivers?
Moderna reported net product sales of $3.1 billion for 2024, a decrease from $6.7 billion in 2023. This decline is primarily attributed to lower sales volumes for its COVID vaccine as the market transitions to a seasonal, endemic phase and faces increased competition. The company also incurred a net loss of $3.6 billion in 2024, an improvement from the $4.7 billion loss in 2023, driven by ongoing research and development investments and strategic cost optimization efforts.
What are the most significant pipeline developments for Moderna in 2024?
Moderna continues to advance its pipeline with 11 programs in late-stage development. Key highlights include positive Phase 3 data for its next-generation COVID vaccine (mRNA-1283), an RSV vaccine for high-risk adults (mRNA-1345), and a flu+COVID combination vaccine (mRNA-1083). The individualized neoantigen therapy (INT) for melanoma, in collaboration with Merck, has completed Phase 3 enrollment and demonstrated sustained benefits. The company is also progressing rare disease therapies for propionic acidemia (PA) and methylmalonic acidemia (MMA).
What are the major risks Moderna faces according to its 10-K filing?
Moderna identifies several key risks, including the uncertainty and evolving dynamics in the COVID and RSV vaccine markets, intense competition from established pharmaceutical companies, and potential challenges in executing cost efficiency and portfolio prioritization efforts. The company also faces risks related to the lengthy and uncertain clinical development process, obtaining regulatory approvals, manufacturing complexities, supply chain management, and intellectual property protection. Market acceptance of new products and reimbursement from third-party payors are also critical factors.
How is Moderna managing its cash and liquidity, and what are its future funding needs?
As of December 31, 2024, Moderna held $9.5 billion in cash, cash equivalents, and investments, providing significant liquidity. The company expects this to be sufficient for its operations and capital expenditures for at least the next 12 months. While product sales are expected to decline further in 2025, ongoing investments in R&D, commercialization, and manufacturing infrastructure will require substantial cash outflows. Moderna relies on a combination of existing cash reserves, potential future product sales, and strategic funding arrangements, such as the agreement with Blackstone Life Sciences, to support its ongoing operations and pipeline advancement.
06—Continue